

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Hazire Oya ALPAR) Conf No.: 4735
Serial No. 09/937,066) Art Unit: 1645
Filed: September 20, 2001) Examiner: JaNa A. Hines
For: IMMUNOSTIMULANTS)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

This paper is being filed pursuant to 37 C.F.R. §1.97(c), before the mailing of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application.

Applicants state that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a

I hereby certify that this correspondence is being electronically filed with the United States Patent Office via EFS Web on September 9, 2010.

/Andrea Cummings/
Andrea Cummings

counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The Commissioner is authorized to charge any additional fee due to Deposit Account No. 11-0855.

Respectfully submitted,
/elena s. polovnikova/

Elena S. Polovnikova
Patent Agent
Reg. No. 52130
Date: September 9, 2010

KILPATRICK STOCKTON LLP
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 41577-263691